Title |
Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor
|
---|---|
Published in |
American Journal of Cardiovascular Drugs, June 2013
|
DOI | 10.1007/s40256-013-0029-0 |
Pubmed ID | |
Authors |
Jeanne Mendell, Hamim Zahir, Nobuko Matsushima, Robert Noveck, Frank Lee, Shuquan Chen, George Zhang, Minggao Shi |
Abstract |
Edoxaban, an oral direct factor Xa inhibitor, is in development for thromboprophylaxis, including prevention of stroke and systemic embolism in patients with atrial fibrillation (AF). P-glycoprotein (P-gp), an efflux transporter, modulates absorption and excretion of xenobiotics. Edoxaban is a P-gp substrate, and several cardiovascular (CV) drugs have the potential to inhibit P-gp and increase drug exposure. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Japan | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 144 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Japan | 1 | <1% |
Netherlands | 1 | <1% |
France | 1 | <1% |
Slovenia | 1 | <1% |
Unknown | 140 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 23 | 16% |
Student > Master | 22 | 15% |
Other | 12 | 8% |
Student > Ph. D. Student | 11 | 8% |
Student > Postgraduate | 11 | 8% |
Other | 36 | 25% |
Unknown | 29 | 20% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 53 | 37% |
Pharmacology, Toxicology and Pharmaceutical Science | 23 | 16% |
Agricultural and Biological Sciences | 8 | 6% |
Nursing and Health Professions | 4 | 3% |
Computer Science | 4 | 3% |
Other | 15 | 10% |
Unknown | 37 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 April 2022.
All research outputs
#2,690,874
of 25,632,496 outputs
Outputs from American Journal of Cardiovascular Drugs
#48
of 474 outputs
Outputs of similar age
#22,349
of 209,811 outputs
Outputs of similar age from American Journal of Cardiovascular Drugs
#1
of 8 outputs
Altmetric has tracked 25,632,496 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 474 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 209,811 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them